Baricitinib in Patients with Refractory Rheumatoid Arthritis | Zendy

Mark C. Genovese | Zendy; Joel Kremer | Zendy; Omid Zamani | Zendy; Charles Ludivico | Zendy; Marek Krogulec | Zendy; Li Xie | Zendy; Scott D. Beattie | Zendy; Alisa E. Koch | Zendy; Tracy Cardillo | Zendy; Terence Rooney | Zendy; William L. Macias | Zendy; Stephanie de Bono | Zendy; Douglas Schlichting | Zendy; Josef S Smolen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Baricitinib in Patients with Refractory Rheumatoid Arthritis

Author(s) -

Mark C. Genovese,

Joel Kremer,

Omid Zamani,

Charles Ludivico,

Marek Krogulec,

Li Xie,

Scott D. Beattie,

Alisa E. Koch,

Tracy Cardillo,

Terence Rooney,

William L. Macias,

Stephanie de Bono,

Douglas Schlichting,

Josef S Smolen

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1507247

Subject(s) - medicine , rheumatoid arthritis , antirheumatic drugs , janus kinase inhibitor , refractory (planetary science) , antirheumatic agents , janus kinase , arthritis , tofacitinib , receptor , physics , astrobiology

In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity in patients with rheumatoid arthritis who had not previously received treatment with biologic disease-modifying antirheumatic drugs (DMARDs).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research